(MENAFN- EIN Presswire)
Myasthenia Gravis companies working in the market are RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, and others.
LAS VEGAS, NV, UNITED STATES, January 13, 2025 /EINPresswire / -- DelveInsight's“Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast
Some of the key facts of the Myasthenia Gravis Market Report:
The Myasthenia Gravis market is expected to experience steady growth throughout the forecast period (2024–2034), with an increase in the market size across the 7MM, driven by the introduction of emerging therapies.
According to DelveInsight's analysis, approximately 45% of all diagnosed prevalent cases of myasthenia gravis in the 7MM are from the US. In 2023, the EU4 countries and the UK together accounted for nearly 125,000 diagnosed prevalent cases of the condition.
In the 7MM, the market primarily focused on refractory treatments, which generated nearly USD 4.95 billion in 2023.
The overall market for Myasthenia Gravis treatment is projected to grow during the forecast period, supported by the development of new and effective therapies such as Nipocalimab, Batoclimab, Descartes-08, and others.
In the 7MM, the EU4 countries and the UK collectively reported nearly 125,000 diagnosed prevalent cases of myasthenia gravis in 2023, with numbers expected to rise during the forecast period (2023-2034). Among the EU4 and the UK, Germany had the highest number of diagnosed cases, totaling 39,000, followed by the UK and France. Conversely, Spain had the fewest diagnosed cases in the region in 2023. In Japan, approximately 32,000 diagnosed prevalent cases of myasthenia gravis were reported in 2023, with a notable increase projected at a significant compound annual growth rate (CAGR).
Key Myasthenia Gravis Companies: Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Harbour BioMed, Novartis, Takeda, DAS Therapeutics, RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, and others
Key Myasthenia Gravis Therapies: SOLIRIS (eculizumab), Nipocalimab, Batoclimab, DESCARTES-08, and others
The Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myasthenia Gravis pipeline products will significantly revolutionize the Myasthenia Gravis market dynamics.
Myasthenia Gravis Overview
Myasthenia gravis is an autoimmune disorder in which the immune system attacks the body's tissues, disrupting the neuromuscular junction, where nerves connect with muscles. The primary targets of the immune attack are the nicotinic acetylcholine receptor (AChR), followed by muscle-specific kinase (MuSK) and lipoprotein receptor-related protein 4 (LRP4). The condition presents with fluctuating, painless muscle weakness, often starting with ocular symptoms like ptosis (drooping eyelids) and diplopia (double vision), though it can also involve oropharyngeal or limb weakness.
The diagnosis of myasthenia gravis is confirmed through electromyography (EMG), pharmacologic testing, and serum antibody assays. EMG studies help confirm a postsynaptic defect, while the clinical response to cholinesterase inhibitors supports the diagnosis. Specific antibodies (e.g., AChR and MuSK) help identify subgroups of the disease, with EMG being essential in patients without detectable antibodies.
Currently, there is no cure for myasthenia gravis, but treatments can manage symptoms and improve quality of life. Standard treatments include cholinesterase inhibitors, immunosuppressants, and biological therapies. In cases of severe symptoms or myasthenic crises, plasmapheresis or intravenous immunoglobulins may be used for rapid relief.
Several promising new treatments are being developed, including Fc receptor antagonists, anti-C5 therapies, interleukin-6 receptor antagonists, and T lymphocyte replacements. These therapies aim to offer new options for managing the condition.
Get a Free sample for the Myasthenia Gravis Market Forecast, Size & Share Analysis Report: Gravis-market
Myasthenia Gravis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Myasthenia Gravis Epidemiology Segmentation:
The Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Diagnosed Prevalence of Myasthenia Gravis in Adults
Diagnosed Prevalence of Myasthenia Gravis in Pediatrics
Diagnosed Prevalence of Myasthenia Gravis by Types
Diagnosed Prevalence of Myasthenia Gravis by Location
Diagnosed Prevalence of Myasthenia Gravis by Severity
Download the report to understand which factors are driving Myasthenia Gravis epidemiology trends @ Myasthenia Gravis Epidemiology Forecast
Myasthenia Gravis Marketed Drugs
SOLIRIS (eculizumab): Alexion, AstraZeneca Rare Disease
Myasthenia Gravis Emerging Drugs
Nipocalimab: Janssen Research & Development, LLC
Batoclimab: Immunovant Sciences GmbH
DESCARTES-08: Cartesian Therapeutics
Myasthenia Gravis Therapies
SOLIRIS (eculizumab), Nipocalimab, Batoclimab, DESCARTES-08, and others
Myasthenia Gravis Key Companies
Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, and others
Myasthenia Gravis Market Outlook
The treatment landscape for myasthenia gravis is diverse, involving a range of therapeutic approaches. Management typically includes the use of cholinesterase enzyme inhibitors, immunosuppressive agents, biological therapies, and, when necessary, thymectomy. Refractory treatment options such as VYVGART (efgartigimod alfa-fcab), SOLIRIS, ULTOMIRIS (Ravulizumab), plasma exchange/IVIG, and other therapies are key revenue drivers in the current market.
The myasthenia gravis market is expected to experience significant growth, driven by the approval of promising new drugs like Nipocalimab, Batoclimab, and Descartes-08. In 2023, the total market size for myasthenia gravis in the 7MM was approximately USD 4,950 million, with strong growth projected during the forecast period.
Among the 7MM, the United States held the largest market share in 2023, accounting for nearly 76% of the total market. The EU4 and the UK generated an estimated USD 893 million in 2023, with substantial growth expected in the coming years. Germany captured the largest share of the European market, followed by the UK, France, and Italy, while Spain had the smallest market share. In Japan, myasthenia gravis represented about 6% of the total market in 2023, with strong growth anticipated over the study period.
Overall, the myasthenia gravis treatment market is expected to expand due to the introduction of new, effective therapies.
Scope of the Myasthenia Gravis Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Myasthenia Gravis Companies: Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, and others
Key Myasthenia Gravis Therapies: Seclidemstat, ZEPZELCA (lurbinectedin), and others
Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies
Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Myasthenia Gravis Market Access and Reimbursement
To know more about Myasthenia Gravis companies working in the treatment market, visit @ Myasthenia Gravis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Myasthenia Gravis Market Report Introduction
2. Executive Summary for Myasthenia Gravis
3. SWOT analysis of Myasthenia Gravis
4. Myasthenia Gravis Patient Share (%) Overview at a Glance
5. Myasthenia Gravis Market Overview at a Glance
6. Myasthenia Gravis Disease Background and Overview
7. Myasthenia Gravis Epidemiology and Patient Population
8. Country-Specific Patient Population of Myasthenia Gravis
9. Myasthenia Gravis Current Treatment and Medical Practices
10. Myasthenia Gravis Unmet Needs
11. Myasthenia Gravis Emerging Therapies
12. Myasthenia Gravis Market Outlook
13. Country-Wise Myasthenia Gravis Market Analysis (2020–2034)
14. Myasthenia Gravis Market Access and Reimbursement of Therapies
15. Myasthenia Gravis Market Drivers
16. Myasthenia Gravis Market Barriers
17. Myasthenia Gravis Appendix
18. Myasthenia Gravis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Myasthenia Gravis Pipeline
"Myasthenia Gravis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myasthenia Gravis market. A detailed picture of the Myasthenia Gravis pipeline landscape is provided, which includes the disease overview and Myasthenia Gravis treatment guidelines.
Myasthenia Gravis Epidemiology
DelveInsight's 'Myasthenia Gravis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Myasthenia Gravis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN13012025003118003196ID1109084461